PhoreMost
Significantly enhancing the potential to advance novel therapeutics for cancers and other health conditions with unmet needs, the company’s platform can identify potentially treatable sites across the human proteome and connect these sites directly to therapeutic functions to develop novel life-changing therapies.
In Q2 2024, the company launched its new drug discovery platform GlueSEEKER™ for the systematic discovery of molecular glue degraders (MGDs) for targeted protein degradation (TPD). The platform integrates advanced computational methods with molecular biology to develop novel degrader therapeutics.
MGDs are a new class of small molecule drug with capabilities that exploit a cell’s proteostasis mechanisms and cause target degradation. This novel approach can potentially treat major diseases from cancer to neurodegeneration and develop new precision medicines faster.
PhoreMost’s investors include Amadeus Capital Partners, Parkwalk, Morningside Ventures, BGF and Meltwind. It recently added $12m to its 2021 Series B raise.
